Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials

Abstract

A B S T R A C T PurposeTo optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy is needed. Therefore, we analyzed gonadal functions in survivors of HL. Patients and MethodsWomen younger than age 40 and men younger than 50 years at diagnosis in ongoing remission at least 1 year after therapy within the German Hodgkin Study Group HD13 to HD15 trials for earlyand advanced-stage HL were included. Hormone parameters, menstrual cycle, symptoms of hypogonadism, and offspring were evaluated. ResultsA total of 1,323 (55%) of 2,412 contacted female and male survivors were evaluable for the current analysis (mean follow-up, 46 and 48 months, respectively). Follicle-stimulating hormone, anti-Mü llerian hormone, and inhibin B levels correlated significantly with therapy intensity (P Ͻ .001). Low birth rates were observed in survivors after advanced-stage treatment within the observation time (women, 6.5%; men, 3.3%). Regular menstrual cycle was reported by more than 90% of female survivors of early-stage HL (recovery time mostly Յ 12 months). After six to eight cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, menstrual activity was strongly related to age (Ͻ v Ն 30 years: 82% v 45%, respectively; P Ͻ .001; prolonged recovery time). Thirty-four percent of women age Ն 30 years suffered severe menopausal symptoms (three-to four-fold more frequently than expected). In contrast, male survivors had mean levels of testosterone within the normal range and reported no increased symptoms of hypogonadism. ConclusionThe present analysis in a large group of survivors of HL provides well-grounded information on gonadal toxicity of currently used treatment regimens and allows risk-adapted fertility preservation and comprehensive support during therapy and follow-up.

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

“…However, pregnancies in women with low or undetectable AMH levels were reported, underlining the need to further analyze the relevance of AMH assessment in female survivors of cancer. The authors concluded that 'AMH is obviously not suited to predict fertility in individual patients; however, low AMH levels might indicate a reduced ovarian reserve and thus an increased risk of future premature ovarian failure' (Behringer et al 2013).…”

“…Recently, Behringer et al (2013) have provided important data on the impact of currently used chemotherapy in Hodgkin lymphoma on gonadal function. The authors evaluated hormone parameters, menstrual cycle, symptoms of hypogonadism, and offspring in women younger than 40 years of age and men younger than 50 years of age at diagnosis in ongoing remission at least 1 year after therapy within two clinical German studies for early-and advanced-Hodgkin lymphoma.…”

Treatment patterns, outcomes and long-term toxicity among patients with Hodgkin’s lymphoma in real world: results of a hospital based registry

“…Общими тенденциями тера-пии являются адаптация объема терапии к риску про-грессии, отказ или снижение объема лучевой терапии, использование препаратов, обладающих минималь-ным канцерогенным потенциалом, сохранение фер-тильности [9][10][11][12][13][14]. Наше исследование показывает, что применение этих принципов на практике нуждается в совершенствовании.…”

Hodgkin lymphoma: MOPP chemotherapy to PD‐1 blockade and beyond

“…Patients receiving ABVD chemotherapy had a five-year failure free survival of 65% compared to 78% for patients receiving escalated BEACOPP-a difference that was statistically significant. The benefits of this treatment approach however have been counterbalanced by increased toxicity with the intensification of the regimen [14,15]. Complications related to escalated BEACOPP have included greater degrees of hematological toxicity and potential infection, as well as longer term risks including infertility, potential stem cell injury, and possible increased leukemic risks.…”